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Summary of main point: A high percentage of patients who tested positive for vancomycin
resistant Enterococcus (VRE) converted to VRE negative after administration of a microbiota-

Abstract

us

Background: Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated

pathogen and a well-known complication among transplant and immunocompromised patients.
We report on stool VRE clearance in a post hoc analysis of the Phase 2 PUNCH CD study

an

assessing a microbiota-based drug for recurrent Clostridium difficile infection.

M

Methods: A total of 34 patients enrolled in the PUNCH CD study received 1 or 2 doses of
RBX2660 (microbiota suspension). Patients were requested to voluntarily submit stool samples
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at baseline and at 7, 30 and 60 days and 6-months after the last administration of RBX2660.
Stool samples were tested for VRE using bile esculin azide agar with 6 µg/ml vancomycin and
gram staining. Vancomycin resistance was confirmed by Etest.

ce

Results: VRE status (at least 1 test result) was available for 30 patients. All stool samples for
19 patients (63.3%, mean age 61.7 years, 68% female) tested VRE negative. Eleven patients
(36.7%, mean age 75.5 years, 64% female) were VRE positive at the first test (baseline or 7-

Ac

day follow-up). Of these patients, 72.7%, n=8 converted to negative as of the last available
follow-up (30 or 60 days or 6-months). Of the other 3: 1 died (follow-up data not available); 1
patient remained positive at all follow-ups; 1 patient retested positive at 6-months with negative
tests during the interim.
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based drug targeted at recurrent Clostridium difficile infection.

3

Conclusions: Although based on a small sample size, this secondary analysis demonstrated

in a recurrent CDI population with RBX2660.

us

Introduction

Vancomycin-resistant Enterococcus (VRE) is a major healthcare-associated pathogen. VRE
infection is a well-known complication among critically ill, transplant and immunocompromised

an

patients [1]. VRE colonization precedes infection, and vancomycin resistance is an independent
predictor of mortality in patients with enterococcal bacteremia [1]. Colonization and infection are

M

also associated with increased hospital length of stay [2,3] and costs [2,3], and carriers are at
increased risk for infection and a source of transmissions to others. Controlling transmission in a
healthcare setting can be challenging [4]. Clostridium difficile infection (CDI), likewise, is a
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challenging healthcare-associated infection (HAI) and can result in severe morbidity and
mortality. CDI is now the most common cause of HAI and the leading cause of gastroenteritisassociated deaths in the U.S. A recent study found that CDI was responsible for approximately
453,000 infections and 29,000 deaths in the US in 2011[5]. Recurrence is an especially

ce

challenging aspect of treating CDI, with up to 25% of patients experiencing disease recurrence,

Ac

usually within 30 days of treatment [6].

Both VRE and CDI share similar risk factors, including contact with the healthcare system,
antimicrobial exposures, acuity of underlying illness, and immunocompromised status [7].
Increased frequencies of VRE colonization and infection have been observed to occur in
tandem with increases in CDI. In a series of hospital inpatients with CDI, VRE colonization was
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the possibility of successfully converting a high percentage of VRE positive patients to negative

4
also found in 58.7% of cases. There was also a greater prevalence of co-infection with multidrug
resistant organisms (MDRO) in the VRE positive patients [8]. Antimicrobial-induced
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perturbation of the gut microbiota may contribute to both VRE and CDI, allowing acquisition and
over growth, and then persistence of colonization. Controlling the spread of VRE in the

healthcare environment is difficult. Patients can remain colonized with VRE for prolonged

us

VRE is extremely difficult if not impossible. While non-absorbed antimicrobials are effective in
suppressing VRE, recurrence of colonization is common [9, 10]. While non-absorbed
antimicrobials are effective in suppressing VRE, recurrence of colonization is com

an

Antimicrobial treatment options can have rate limiting toxicities, and resistance to antimicrobials
with activity against VRE is increasing. VRE infection also significantly increases length of stay

M

and hospitalization costs [2,11].

There is growing recognition that commensal bacteria present in the intestinal microbiome play
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an important role in colonization resistance to pathogens, including C. difficile and VRE, and
that antimicrobial use can disrupt this protection and enable a cycle of persistence/reinfection.
In the case of CDI, studies suggest that restoration of the gut microbiota is necessary to prevent
or mitigate recurrence [12]. Fecal microbiota transplantation (FMT) has been used to

ce

repopulate the intestines with normal microbiota and has been demonstrated as effective in the
treatment of recurrent CDI with few adverse events [13, 14]. We report on clearance of VRE in
stool in a secondary analysis of the PUNCH CD study, a Phase 2 open-label study assessing

Ac

the safety and efficacy of RBX2660, a microbiota-based drug, in a population of patients with
recurrent CDI.
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periods of time, serving as a reservoir for transmission and infection to others. Decolonization of
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Methods
Forty patients with recurrent CDI at 11 centers in the U.S. were enrolled in the PUNCH CD
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study between August 15 and December 16, 2013 [15]. Major inclusion criteria were: age ≥ 18

years old and at least two recurrences of CDI after a primary episode or at least two episodes of
severe CDI resulting in hospitalization. Completion of a 10-14 day course of oral antimicrobials

us

was required, followed by a 24-48 hour washout period prior to RBX2660 administration. A

single dose of RBX2660 was administered via enema. A second dose was permitted if CDI
recurrence was suspected within 8 weeks of the first dose. No antimicrobials for the treatment of

an

CDI or bowel prep were given before the second dose. Major exclusion criteria were: history of
inflammatory bowel disease (ulcerative colitis, Crohn’s disease or microscopic colitis); irritable

M

bowel syndrome; chronic diarrhea; celiac disease; colostomy; evidence of active, severe colitis;
planned surgery requiring perioperative antibiotics within 6 months of study enrollment;

RBX2660
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compromised immune system and white blood cell count <1000 cells/µL.

RBX2660 is a microbiota-based drug sourced from live human-derived microbes. Donors
underwent a comprehensive initial health and lifestyle questionnaire and then provided blood

ce

and stool samples that were tested for a wide variety of pathogens. RBX2660 is produced with
Good Manufacturing Practices (GMP) and a standardized chain of custody. Product is stored in
a secure location at ≤ -80 ºC prior to shipment. Each 150 mL dose (50 g of stool and 0.9%

Ac

saline/polyethylene glycol 3350 vehicle) contains ≥ 107 microbes/mL and is available in a single
dose ready-to-use enema bag.
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for CDI, the last 7 days of which were standardized to oral vancomycin (125 mg four times daily)
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VRE Testing Protocol
Baseline stool testing of the study patients included culture for VRE. Additionally, patients were
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requested to voluntarily submit stool samples at 7, 30 and 60 days and 6-months after the last
administration of RBX2660. Stool samples were shipped on ice to Fairview Diagnostic

Laboratories, Minneapolis, MN, USA laboratory via overnight delivery. Lab requirements for

collection. To determine the presence of VRE, stool was inoculated onto bile esculin azide agar

us

with 6 μg/ml vancomycin (Remel, Lenaxa, Kansas, USA). Enterococcal isolates were identified
based on colony morphology, Gram stain, and biochemical testing. Suspected enterococcal

M

was confirmed by Etest,

an

isolates were sub-cultured on blood agar with a vancomycin disk and vancomycin resistance

Antimicrobial Use Exposure Post-RBX2660 Administration
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After RBX2660 administration, physicians could treat patients with antimicrobials as medically
necessary. Medication use was collected on the case report form in free-form text for all patients
enrolled in the PUNCH CD study. Data on post-RBX2660 antimicrobial administration was
abstracted and placed on a timeline for the purposes of determining whether or not VRE was

ce

detectable in fecal specimens throughout the course of the study.

Ac

Definitions

For the PUNCH CD study, successful treatment of CDI was defined as the absence of
Clostridium difficile associated diarrhea at 56 days after the last dose of RBX2660. For the VRE
analysis, patients were grouped into always negative and positive at least once. A baseline, i.e.
pre-RBX2660 administration, stool specimen was not collected for many patients, therefore both
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testing were fresh stool, within 72 hours of collection; refrigerated if not tested directly after

7
the pre-RBX2660 and day 7 follow-up stool specimens were used to identify patients likely
colonized with VRE at time of RBX2660 administration. VRE clearance was defined as no stool

Statistical Methods

us

Descriptive statistics were used for data analysis. This secondary analysis was not powered to

Results
Baseline Characteristics

M

an

determine statistical significance.
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A total of 34 patients received 1 or 2 doses of RBX2660. Of these, 30 patients had at least 1
stool sample available for VRE testing. Of these patients, the mean age was 66.7 years with a
range of 26.7-89.5 years. Twenty (66.6%) were female and 29 (96.6%) were white (Table 1).
Patients with at least one stool positive for VRE were older than patients without stool positive
for VRE (75.5 versus 61.7 years old). Prior to study enrollment, patients had been on a variety

ce

of CDI treatment regimens, primarily standard dose vancomycin but also vancomycin taper and

Ac

standard dose fidaxomicin; 1 patient had been on a fidaxomicin taper.

VRE Status

All stool samples submitted for testing were found acceptable by the laboratory performing VRE
testing. A total of 30/34 (88%) of patients treated with RBX2660 submitted at least 1 stool for
VRE testing (Table 2). All stool samples for 19 patients were negative for VRE; 11 patients were
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specimens positive for VRE after at least one positive stool test.

8
positive for VRE at the first test (baseline or 7-day follow-up). Of the patients who were positive
for VRE at least once, 72.7% (n=8) converted to negative as of the last available follow-up. The
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proportion of patients testing positive for VRE after the last dose of RBX2660 decreased over
time (Figure 1). Three patients were classified as having failed to clear VRE: One patient died of
respiratory failure unrelated to RBX2660 administration soon after FMT. Follow-up VRE

us

follow-ups (prescribed a 14-day course of vancomycin at 16 days post-RBX2660

administration). The third patient retested positive at 6 months after having negative tests in the
interim. This patient was VRE positive at 9 days post-RBX 2660 administration and then tested

an

VRE negative at the 1- month and 2-month follow-ups. Subsequently, this patient developed
several episodes of recurrent CDI and received 8 courses of antimicrobials between the last

M

negative stool test for VRE and the 6 month specimen which was positive.
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Antimicrobial use post-RBX2660 administration was analyzed for the 11 patients who were VRE
positive on their first test. Patients received antimicrobials post-RBX2660 administration
primarily for CDI or diarrhea but also for pneumonia, urinary tract infection, sinus infection,
abscess, and non-specified bacterial infection. Of these patients, 6 received antimicrobials postRBX2660 administration; the mean duration of their antimicrobial exposure post-RBX2660

ce

administration was 6.2 (range 1 to 14) days. Considering only the patients who were initially
VRE positive and converted to VRE negative at last assessment, 4 received antimicrobials post-

Ac

RBX2660 administration; mean duration was 7.0 (range 2 to 13) days. In the 11 patients who
tested VRE positive at least once, the antimicrobials prescribed post-RBX2660 administration
were: vancomycin (n=5); fidaxomicin (n=3); metronidazole (n=1); ciprofloxacin (n=2); amoxicillin
(n=2); doxycycline (n=1); and other (n=5). Analysis of variance shows that antimicrobial use was

concentrated in 2 of the 11 patients.
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Discussion
VRE colonization and CDI share similar risk factors, and VRE infection and colonization have
been observed to occur in tandem with CDI. Of 158 cases of CDI evaluated by Fujitani, et al.

[8], 55.7% were colonized with VRE. In this subset of 30 patients with recurrent CDI who were

us

for acquiring and developing infections from both VRE [16-18] and C. difficile is antimicrobial

exposure [19-21]. There is recognition that antimicrobials disturb the microbiome and facilitate

an

selection and expansion of resistant bacteria [22]. Concurrent with increased understanding of
the role of the commensal bacteria in preventing colonization and infection with CDI and VRE,
as well as other MDROs, has prompted a look at use of microbiota-based approaches to

M

prevent colonization and infection due to these organisms. Recent work has demonstrated
commensal bacteria provide not only colonization resistance, but also are involved in immune
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processes that stimulate the development of antimicrobial factors [23]. Antimicrobials, by killing
the commensal bacteria, decrease the diversity of the intestinal microbiota, enabling pathogens
such as VRE and C. difficile, among others, to colonize and proliferate [24]. A normal intestinal
microbiota, therefore, is necessary for colonization resistance. FMT has been demonstrated
effective against recurrent CDI [25,26] and to restore diversity in the gut microbiota in

ce

successfully treated patients [27,28].

Ac

Based on the positive experience with the use of FMT for recurrent CDI, FMT is now being
considered for the treatment of many other conditions, and it has been suggested that it may be
effective in clearing VRE and other MDROs by restoring colonization resistance [22,23]. Case
reports have described the use of FMT for MDRO decolonization [29,30]. Jang et al. [29]
reported that a patient with severe refractory CDI who was also colonized with VRE was cured
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enrolled PUNCH CD study, 36.7% had stool positive for VRE at baseline. The major risk factor
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of CDI with FMT. However, VRE was cultured from the stool throughout the 3-month follow-up.
Crum-Cianflone et al. [30] reported one case where FMT successfully cured relapsing CDI and
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several MDROs including VRE. Stripling, et al. reported that FMT cleared VRE and CDI in a
woman with orthotopic cardiac and single cadaveric kidney transplants complicated by multiple
episodes of VRE infection and CDI post-transplant. Between the time of organ transplants and

us

1-year after FMT [31]. Singh et al. reported on eradication of extended spectrum beta-

lactamase (ESBL) producing Escherichia coli (E. coli) in a man with a renal allo-transplant with
end-stage renal disease consequent to recurrent episodes of pyelonephritis post-transplant [32].

an

Following removal of the transplanted kidney, he remained colonized. Following FMT, the ESBL
cleared at 12-weeks follow-up and he was then placed on the waiting list for renal

M

transplantation.

In this case series, RBX2660, a microbiota-based drug undergoing Phase 2 study for recurrent
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CDI, was associated with clearance of VRE in a high percentage of patients who were colonized
at time of drug delivery (72.7%, 8/11). For two of the patients who failed to clear VRE, the
treatment also failed to prevent recurrence of CDI. The recurrence of CDI in those patients may
indicate that the gastrointestinal microbiota was not effectively reestablished after treatment with

ce

RBX2660. The proportion of patients with VRE detected in stool after the last dose of RBX2660
decreased over the course of 6-month follow-up. Of note, it is possible RBX2660 suppressed
VRE below the threshold of the culture method used to detect VRE colonization, as

Ac

demonstrated by the patient in whom VRE was detected again after exposure to multiple
courses of antimicrobials. Repeat exposures to antimicrobials are associated with persistence of
VRE detection in stool [16-18]. Although VRE may no longer be detected in the absence of
additional antimicrobial exposures, Donskey et al. [16] found VRE can be detected again when
a person is later exposed to antimicrobials. However, VRE was not detected again in 4 of 6
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FMT, the patient was hospitalized 18 times. The patient had no further CDI or VRE infections at

11
(67%) patients positive at first test who converted to negative after RBX2660 who received
additional antimicrobials after receipt of RBX2660. This suggests that VRE was truly “cleared”
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from the colon of several patients. It should be noted, however, that in some cases the absence
of recurrence could potentially be related to antimicrobials with a low propensity to promote VRE
colonization (e.g., fidaxomicin, doxycycline). RBX2660 may represent a potentially promising

an

us

infection.

Limitations

M

The findings in this analysis have a number of limitations. This was a small secondary analysis
conducted in the context of a Phase 2 open-label assessment of RBX2660 for recurrent CDI,
and there was no comparator arm. However, natural history observation estimates a median
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time to clearance of VRE carriage at 26 weeks,4 whereas the majority of evaluable patients
appeared to clear in a shorter interval. Patient compliance with stool submission post-RBX2660
administration varied over the course of follow-up. The findings should be confirmed in a larger

ce

study with VRE decolonization as a primary outcome using a placebo arm for comparison.

Conclusions

Ac

This secondary analysis demonstrates the possibility of converting a high percentage of VRE
positive patients to negative with RBX2660. Based on an analysis of post-RBX2660
antimicrobial exposure, it appears that the VRE conversion results may be durable. Additional
study in a larger prospective trial is needed to confirm these results.
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Mean BMI, range k/m2

24.4 (15-37)

History of cardiovascular disease, %

16 (53.3)

History of gastrointestinal comorbidity, %

18 (60)

61.7 (26.7-77.8)

75.5 (47.6-89.5)

13 (68.4)

7 (63.6)

19 (100)

10 (90.9)

23.9 (15-31)

25.3 (19-37)

10 (52.6)

6 (54.5)

ed

ep
t
Ac
c

At least 1 VRE (+)
n=11

M
an
u

Mean age, range, y

rip
t

Stool tested for VRE

sc

Parameter

11 (57.9)
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Table 1. Baseline Characteristics

7 (63.6)

17

Entire PUNCH CD
cohort
n = 34

66.8 (26.7 – 89.6)
23 (67.6)
32 (94.2)
24.4 (15-37)
19 (55.9)
21 (61.8)

Antimicrobials

Number

CDI Status

Post RBX2660
Baseline

7 days

30 days

60 days

6 months

VRE
Cleared

+

-

-

-

+

No

Prescriptions, n

Ciprofloxacin, 2

M
an
u

1

rip
t

VRE Test Status

RBX2660

sc

Patient

Outcome

1

Success

2

Failure

Penicillin, 1

Vancomycin, 2

+

+

+

+

-

Yes

Vancomycin, 1

-

4

NA

+

NA

5

NA

+

-

6*

NA

+

-

NA

-

ep
t

-

Yes

None

1

Success

-

-

Yes

None

2

Success

-

NA

Yes

None

2

Success

NA

NA

Cefuroxime, 1

2

Success

Ac
c

+

ed

Fidaxomicin, 1

3

CDI

Doses

Amoxicillin, 2

2
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Table 2. VRE Culture Results for Patients with at Least 1 Positive Culture for VRE

NA

18

+

+

+

+

No

Vancomycin, 1

8

NA

-

+

-

NA

Yes

None

9

NA

+

-

-

-

Yes

Sulfamethoxazole, 1

2

Success

1

Success

sc

2

+

+

-

-

-

11

+

+

-

-

-

M
an
u

Trimethoprim, 1

10

Yes

None

1

Success

Yes

Doxycycline, 1

2

Success

Metronidazole, 1

ed

Macrobid, 1

VRE = vancomycin resistant Enterococcus; CDI=Clostridium difficile infection; NA=not available

ep
t

VRE status reflects status after the last dose of RBX2660.

Failure

rip
t

NA
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Ac
c

* Died 35 days after last dose of RBX2660 of causes unrelated to drug administration; follow-up data on VRE status was unavailable.

19

20
Figure Legends
Figure 1. The percentage of patients testing VRE positive after the last dose of RBX2660
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ed
ce
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decreased over time.

